We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Platelet-Like Particles Augment Natural Blood Clotting

By HospiMedica International staff writers
Posted on 01 Oct 2014
A new class of synthetic particles could augment natural blood clotting for the emergency treatment of traumatic injuries, according to a new study.

Researchers at Georgia Institute of Technology (Atlanta, USA) and Emory University (Atlanta, GA, USA) developed the synthetic platelet-like particles (PLPs), from soft and deformable hydrogel precursor materials. The synthetic PLPs are bound to an antibody that has a high affinity to the polymerized form of fibrin, and a low affinity for fibrinogen. As a result, they are only activated when the body’s natural clotting process is triggered by thrombin-activated fibrin.

Testing done in animal models and in a simulated circulatory system suggest that the particles are effective at slowing bleeding, and can safely circulate in the bloodstream. The in vitro and in silico analyses also demonstrated that after clotting, the PLPs also actively collapse fibrin networks, an emergent behavior that mimics in vivo clot contraction. According to the researchers, the PLPs could offer doctors a new option for curbing surgical bleeding and addressing some clotting disorders without the need for transfusions of natural platelets. The study was published on September 7, 2014, in Nature Materials.

“When used by emergency medical technicians in the civilian world or by medics in the military, we expect this technology could reduce the number of deaths from excessive bleeding,” said lead author Ashley Brown, PhD, of the Georgia Tech school of chemistry and biochemistry. “If EMTs and medics had particles like these that could be injected and then go specifically to the site of a serious injury, they could help decrease the number of deaths associated with serious injuries.”

“For a patient with insufficient platelets due to bleeding or an inherited disorder, physicians often have to resort to platelet transfusions, which can be difficult to obtain,” added co-author Wilbur Lam, MD, of the Emory school of medicine department of pediatrics. “These particles could potentially be a way to obviate the need for a transfusion. Though they don’t have all the assets of natural platelets, a number of intriguing experiments have shown that the particles help augment the clotting process.”

Related Links:

Georgia Institute of Technology
Emory University


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Trocar
TAN RoTaLock Trocar
New
Open Stapler
PROXIMATE Linear Cutter

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more